Journal of Clinical and Aesthetic Dermatology

AUG 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/870497

Contents of this Issue

Navigation

Page 62 of 67

63 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY August 2017 • Volume 10 • Number 8 with commonly used medications, and unwanted side effects. The study utilized nitric oxide as a treatment and a well-known nanoparticle as the delivery system for the nitric oxide, in order to attack deep and difficult to reach infections. * For more information, https://www.sciencedaily.com/releases/2017/07/17073 1114627.htm USING PROBIOTICS TO HEAL WOUNDS A group of researchers are harnessing a "friendly" bacteria's antibacterial properties to prevent pathogen infections. Using extracts from two strains of bacteria not native to the skin (L. rhamnosus GG and L. reuteri), Catherine O'Neill, PhD, senior lecturer in the Division of Musculoskeletal and Dermatological Science at the University of Manchester in the United Kingdom, along with her team, reported that these bacterial extracts promoted cell migration and cell division in a wound healing model. Additional studies support the potential for probiotic use for wound treatment, including four other studies that reported improved wound healing in mice through the use of oral probiotics. One study reported faster healing in burn patients who took a probiotic. While initial anecdotal reports seem promising, experts say that there needs to be more research conducted. Baljit Dheansa, lead surgeon for burns at Queen Victoria Hospital in East Grinstead, United Kingdom, asserts that, "if probiotics are to usefully enter the wound healing arena, we need to make sure that we conduct well-constructed research studies that will help us establish a proper evidence base for their use in real wounds in humans rather than in the lab." * For more information, http://www.medicalnewstoday.com/articles/318765.php 9 TH WORLD CONGRESS OF MELANOMA AND 14 TH INTERNATIONAL CONGRESS OF THE SOCIET Y FOR MELANOMA RESEARCH The 9 th World Congress of Melanoma and 14 th International Congress of the Society for Melanoma Research will be held at the Brisbane Convention and Exhibition Centre on October 18 to 21, 2017, in South Brisbane, Australia. * For more information, http://worldmelanoma2017.com for details. VITILIGO AND EMERGING SKIN REPIGMENTATION OPTIONS Medscape recently repor ted that between two million and five million Americans are affected by vitiligo, but the FDA has yet to approve one single drug for repigmentation treatment. However, new treatments for vitiligo showing promise, such as Wnt agonists, Nr f2 activators, and JAK inhibitors (e.g., ruxolitinib 1.5% cream.) Pearl Grimes, MD, director of the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, says of the condition, "My hope is that five years from now, vitiligo will be like psoriasis. We'll have multiple new agents we can pick and choose from based on the clinical features of a patient with vitiligo." * For more information, http://www.medscape.com/viewar ticle/883652 FEAR KEEPS MANY ECZEMA PATIENTS FROM USING STEROID CREAMS A new study published in the Journal of the American Medical Association examined 16 previously published studies for patient attitudes toward the use of cor ticosteroids in the treatment of eczema. The study concluded that as many as four out of five patients are afraid to use topical cor ticosteroids due to the bad reputation that steroids have developed. The study specified that the sources from which patients were receiving information about cor ticosteroids included physicians, friends and relatives, broadcast media, print media, and the internet. Dr. Richard Antaya, director of pediatric dermatology at Yale School of Medicine, says that the side effects that patients fear, including stretch marks; thinning, thickening, and darkening of the skin; acne; infected hair follicles; glaucoma; and cataracts, are mostly from improper or chronic use of high-potency steroids. "The risks from using shor t-term low potency steroids are vastly lower," Antaya added. * For more information, http://www.medscape.com/viewar ticle/883437 SCIENTISTS FIND SUNSCREEN POTENTIAL IN ANTARCTIC PLANTS Scientists in Chile have discovered molecules in two species of Antarctic flowers that protect the plants from solar radiation and could potentially be used in sunscreen for humans and protection for vulnerable crops. The plants, Colobathus quitensis (pearlwort) and Deschampsia antarctica (hair grass), are the only two flowering plants in Antarctica, and grow around the more temperate areas of the region. Researchers identified a group of molecules in the flowers that enable the plants to withstand radiation damage. The university is seeking commercial partners to develop spin-off products from the research. * For more information, visit http://www.medscape.com/viewarticle/883466 COULD VITAMIN B-3 HELP TO PREVENT MELANOMA? A new review suggests that nicotinamide could help to prevent melanoma. Dr. Gary Halliday, of the University of Sydney in Australia, and colleagues reviewed studies that had previously investigated the effects of nicotinamide against melanoma cancer cells. The results suggest that the vitamin may be an effective candidate for prevention, especially for patients at high risk of melanoma. In light of these results, Dr. Halliday and the team suggested further investigation through "randomized placebo-controlled trials…to determine the efficacy and safety of NAM (nicotinamide) for melanoma prevention in high-risk patients." * For more information, http://www.medicalnewstoday.com/articles/ 318876.php JCAD N E W S & T R E N D S

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - AUG 2017